Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Discloses GenturaDx Loss of $19.8M in 2011, $18.5M in H1 2012

NEW YORK (GenomeWeb News) – Luminex today disclosed the finances of GenturaDx, a molecular diagnostic test firm that it acquired for $50 million during the summer.

In a document filed with the US Securities and Exchange Commission, Luminex said that for full-year 2011, GenturaDx recorded no revenues and a net loss of $19.8 million. The company spent $10.1 million on R&D and $3.5 million on SG&A.

For the first six months of 2012, GenturaDx also saw no revenues and a net loss of $18.5 million. R&D costs totaled $6.2 million, while SG&A costs were $5.0 million.

On a pro forma basis, treating GenturaDx as if it were part of Luminex during full-year 2011, the combined company posted $184.3 million in revenues and a profit of $5.2 million, or $.12 per share, Luminex said. R&D spending was $43.5 million, and SG&A totaled $68.4 million.

Luminex earlier this year reported full-year 2011 revenues of $184.3 million and a profit of $14.5 million, or $.34 per share, on a GAAP basis, not including GenturaDx. R&D costs totaled $33.4 million, and SG&A spending totaled $64.9 million.

For the six months ended June 30, 2012 the combined companies had revenues of $97.0 million on a pro forma basis, and a profit of $2.4 million, or $.06 per share. The combined companies spent $25.2 million on R&D and $36.2 million on SG&A.

On a GAAP basis, Luminex recorded $97.0 million in revenues during the first half of 2012 resulting in a profit of $6.5 million, or $.15 per share. R&D costs came in at $19.1 million, while SG&A costs were $34.8 million.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.